

Severe COVID-19 outcomes after full vaccination of primary care patients: a  
pooled analysis of national prospective cohort studies of England, Northern Ireland, Scotland, and Wales

Lancet, The

400, 1305-1320

DOI: [10.1016/s0140-6736\(22\)01656-7](https://doi.org/10.1016/s0140-6736(22)01656-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prioritisation of COVID-19 boosters in the omicron era. <i>Lancet, The</i> , 2022, 400, 1282-1283.	13.7	1
2	New boosters are here! Who should receive them and when?. <i>Lancet Infectious Diseases, The</i> , 2022, , .	9.1	3
3	Data saves lives: bottom-up, professionally-led endorsement would increase the chance of success. <i>British Journal of General Practice</i> , 2022, 72, 512-513.	1.4	3
6	COVID-19 Vaccination among a Population Experiencing Homelessness: A Survey in Italy. <i>Vaccines</i> , 2022, 10, 2118.	4.4	6
7	Implementing Translational Research to Understand the Future of COVID-19 and Its Long-Term Consequences: A Degrowth Perspective or the Transformation of a Global Emergency?. <i>Biomedicines</i> , 2023, 11, 117.	3.2	0
8	COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales: A national prospective cohort study. <i>Vaccine</i> , 2023, 41, 1378-1389.	3.8	3
10	Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai. <i>Emerging Microbes and Infections</i> , 2023, 12, .	6.5	12
12	COVID-19 mRNA Vaccine Effectiveness against Elderly Frail People. <i>Medicina (Lithuania)</i> , 2023, 59, 202.	2.0	2
14	Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 71, 104548.	2.0	1
15	Combining viral genomics and clinical data to assess risk factors for severe COVID-19 (mortality, ICU) Tj ETQq1 1 0.784314 rgBT /Ove 2023, 18, e0283447.	2.5	0
16	The Two-Way Route between Delirium Disorder and Dementia: Insights from COVID-19. <i>Neurodegenerative Diseases</i> , 2022, 22, 91-103.	1.4	1
17	Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece. <i>Vaccine</i> , 2023, 41, 2343-2348.	3.8	5
19	SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies. <i>European Journal of Epidemiology</i> , 2023, 38, 237-242.	5.7	7
20	Change over Time in the Risk of Death among Japanese COVID-19 Cases Caused by the Omicron Variant Depending on Prevalence of Sublineages. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2779.	2.6	2
21	Population-based evaluation of the effectiveness of nirmatrelvirâ€“ritonavir for reducing hospital admissions and mortality from COVID-19. <i>Cmaj</i> , 2023, 195, E220-E226.	2.0	23
22	AdvancesÂinÂnovel devices forÂthe treatment of heart failure. <i>Heart Failure Reviews</i> , 0, , .	3.9	2
24	Effectiveness and safety of coronavirus disease 2019 vaccines. <i>Current Opinion in Pulmonary Medicine</i> , 2023, 29, 138-142.	2.6	1
25	Value of Laboratory Indicators in Predicting Pneumonia in Symptomatic COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1159-1170.	2.7	4

#	ARTICLE	IF	CITATIONS
26	The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	3
27	Vaccine-induced or hybrid immunity and COVID-19-associated mortality during the Omicron wave. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 0, , .	0.9	2
28	Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study â€” Hohhot City, Inner Mongolia Autonomous Region, China, 2022. <i>China CDC Weekly</i> , 2023, 5, 218-222.	2.3	3
29	Immune responses to <sc>COVID</sc>â€19 booster vaccinations in intensively <sc>antiâ€CD38</sc> antibody treated patients with ultraâ€highâ€risk multiple myeloma: results from the Myeloma UK (<sc>MUK) <i>nine</i> OPTIMUM</sc> trial. <i>British Journal of Haematology</i> , 2023, 201, 845-850.	2.5	4
30	Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). <i>RMD Open</i> , 2023, 9, e002871.	3.8	4
31	Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: author's response. <i>Clinical Microbiology and Infection</i> , 2023, , .	6.0	0
32	Risk Indicators of Sarcoidosis Evolution-Unified Protocol (RISE-UP): protocol for a multi-centre, longitudinal, observational study to identify clinical features that are predictive of sarcoidosis progression. <i>BMJ Open</i> , 2023, 13, e071607.	1.9	1
33	Cellular and molecular biomarkers of long COVID: a scoping review. <i>EBioMedicine</i> , 2023, 91, 104552.	6.1	20
34	Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 914-921.	9.1	54
35	Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>Clinical Microbiology and Infection</i> , 2023, 29, 979-999.	6.0	5
36	2023 Chinese Expert Consensus on the impact of COVID-19 on the management of cardiovascular diseases. <i>Cardiology Plus</i> , 0, Publish Ahead of Print, .	0.7	0
37	Impacts of pregnancy and menopause on COVID-19 severity: a systematic review and meta-analysis of 4.6 million women. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 755-765.	0.5	1
39	Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study. <i>EClinicalMedicine</i> , 2023, 61, 102040.	7.1	4
40	Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 1257-1265.	9.1	9
41	Dynamic Trends and Underlying Factors of COVID-19 Vaccine Booster Hesitancy in Adults: Cross-Sectional Observational Study. <i>JMIR Public Health and Surveillance</i> , 0, 9, e44822.	2.6	2
42	Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 1130-1142.	9.1	9
44	Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	3
45	Early Outcomes of SARS-CoV-2 Infection in a Multisite Prospective Cohort of Inpatient Veterans. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	0

#	ARTICLE	IF	CITATIONS
46	Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing. <i>Lancet, The</i> , 2023, , .	13.7	2
47	Moving towards a precision approach for prevention of severe COVID-19 – Authors' reply. <i>Lancet, The</i> , 2023, 401, 1424.	13.7	0
48	Moving towards a precision approach for prevention of severe COVID-19. <i>Lancet, The</i> , 2023, 401, 1423-1424.	13.7	1
49	Development and validation of a prediction model based on comorbidities to estimate the risk of in-hospital death in patients with COVID-19. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
50	Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2. <i>Viruses</i> , 2023, 15, 1449.	3.3	3
52	SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. <i>Nature Medicine</i> , 2023, 29, 1760-1774.	30.7	27
53	Which Factors Were Related to the Number of COVID-19 Cases in the 2022/2023 Season Compared to the 2021/2022 Season in Europe?. <i>Journal of Clinical Medicine</i> , 2023, 12, 4517.	2.4	0
54	A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines. <i>Gut Microbes</i> , 2023, 15, .	9.8	2
56	Development and validation of a prediction model for mechanical ventilation based on comorbidities in hospitalized patients with COVID-19. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
58	Vaccination After SARS-CoV-2 Infection and Postâˆ’COVID-19 Condition. <i>JAMA Internal Medicine</i> , 0, , .	5.1	0
60	Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. <i>Lancet Rheumatology, The</i> , 2023, 5, e461-e473.	3.9	4
61	Embracing dynamic public health policy impacts in infectious diseases responses: leveraging implementation science to improve practice. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	1
62	Multi-omics Approach in Kidney Transplant: Lessons Learned from COVID-19 Pandemic. <i>Current Transplantation Reports</i> , 0, , .	2.0	0
63	Robust generation of neutralising antibodies against Omicron variants following bivalent mRNA booster vaccine in elderly people aged >80 years. <i>Journal of Infection</i> , 2024, 88, 48-50.	3.3	0
64	COVID-19 and cardiovascular disease in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	2
66	Comorbidities, symptoms and end-of-life medication use in hospitalised decedents before and during the COVID-19 pandemic: a retrospective regional cohort study in Ottawa, Canada. <i>BMJ Open</i> , 2023, 13, e075518.	1.9	0
67	High Burden of COVID-19-Associated Pulmonary Aspergillosis in Severely Immunocompromised Patients Requiring Mechanical Ventilation. <i>Clinical Infectious Diseases</i> , 2024, 78, 361-370.	5.8	6
68	The future of vaccination in Latin America: learning from the COVID-19 pandemic. <i>Current Opinion in Immunology</i> , 2023, 85, 102390.	5.5	0

#	ARTICLE	IF	CITATIONS
69	Interwoven challenges of covid-19, poor diet, and cardiometabolic health. <i>BMJ, The</i> , 0, , e076810.	6.0	1
70	Elevated risk of multimorbidity post-COVID-19 infection: protective effect of vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2024, 117, 125-132.	0.5	0
71	Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. <i>Lancet Regional Health - Europe, The</i> , 2023, 35, 100747.	5.6	8
72	Effects of the COVID-19 pandemic on life expectancy at birth at the global, regional, and national levels: A joinpoint time-series analysis. <i>Journal of Global Health</i> , 0, 13, .	2.7	1
74	COVID-19 and Alzheimer's Disease Share Common Neurological and Ophthalmological Manifestations: A Bidirectional Risk in the Post-Pandemic Future. <i>Cells</i> , 2023, 12, 2601.	4.1	0
75	Humoral and cellular immunity against different SARS-CoV-2 variants in patients with chronic kidney disease. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
76	Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
77	Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCCELERATE trial in adults ≥75 years (EU-COVAT-1). <i>Vaccine</i> , 2023, 41, 7166-7175.	3.8	0
78	Real-world data analysis of post-COVID-19 condition risk in older patients. <i>Age and Ageing</i> , 2023, 52, .	1.6	0
79	Risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune-suppressive drugs: A nationwide cohort study of US Veterans. <i>Transplant Infectious Disease</i> , 2024, 26, .	1.7	1
80	Long-term trends in the protection against severe courses of COVID-19 by vaccination. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 0, , .	0.9	0
81	Development and validation of a clinical prediction model for 90-day venous thromboembolism risk following total hip and total knee arthroplasty: a multinational study. <i>Journal of Thrombosis and Haemostasis</i> , 2023, , .	3.8	1
82	Lessons from the English primary care sentinel network's response to the COVID-19 pandemic. <i>Lancet Infectious Diseases, The</i> , 2024, 24, 14-16.	9.1	0
83	Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales. <i>Lancet Regional Health - Europe, The</i> , 2024, 37, 100816.	5.6	0
84	Using genomics to understand severe COVID-19. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	0
85	Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study. <i>Journal of Microbiology, Immunology and Infection</i> , 2024, 57, 76-84.	3.1	0
86	Development and validation of Robust and Interpretable Early Triage Support system for patients hospitalized with COVID-19: Predictive algorithm modeling and interpretation study (Preprint). <i>Journal of Medical Internet Research</i> , 0, , .	4.3	0
87	Acute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2024, 45, 069-087.	2.1	0

#	ARTICLE	IF	CITATIONS
88	Risk of COVID-19-associated pulmonary aspergillosis: time for a nuanced approach to antifungal prophylaxis?. <i>Lancet Respiratory Medicine</i> , 2024, 12, 183-185.	10.7	0
89	Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
90	Survival Characteristics of Older Patients Hospitalized With COVID-19: Insights From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Journal of the American Medical Directors Association</i> , 2024, 25, 348-350.	2.5	0
91	The association between COVID-19 vaccination and confirmed patients with hospitalization in Omicron era: A retrospective study. <i>Medicine (United States)</i> , 2023, 102, e36777.	1.0	0
93	Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England. <i>Nature Communications</i> , 2024, 15, .	12.8	0
94	Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis. <i>BMC Public Health</i> , 2024, 24, .	2.9	0
95	Social network risk factors and COVID-19 vaccination: A cross-sectional survey study. <i>Vaccine</i> , 2024, 42, 891-911.	3.8	0
96	SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. <i>Science Translational Medicine</i> , 2024, 16, .	12.4	4
97	Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 “ Veterans Health Administration, March–September 2022. <i>Morbidity and Mortality Weekly Report</i> , 2024, 73, 57-61.	15.1	0
98	Disparities in COVID-19 mortality amongst the immunosuppressed: A systematic review and meta-analysis for enhanced disease surveillance. <i>Journal of Infection</i> , 2024, 88, 106110.	3.3	2
99	Dysregulated platelet function in patients with postacute sequelae of COVID-19. <i>Vascular Medicine</i> , 2024, 29, 125-134.	1.5	0
100	Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study. <i>Annals of Medicine</i> , 2024, 56, .	3.8	0
101	Immune Response to COVID-19 Vaccination in Frontline Healthcare Workers. <i>Vaccines</i> , 2024, 12, 199.	4.4	0
102	Severe COVID-19 in Vaccinated Adults With Hematologic Cancers in the Veterans Health Administration. <i>JAMA Network Open</i> , 2024, 7, e240288.	5.9	0
103	Risk of Severe COVID-19-Related Outcomes among Patients with Cirrhosis: A Population-Based Cohort Study in Canada. <i>Viruses</i> , 2024, 16, 351.	3.3	0
104	AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study. <i>Journal of Infection</i> , 2024, 88, 106129.	3.3	0
105	Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. <i>Infection</i> , 0, , .	4.7	0
106	B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience. <i>Frontiers in Medicine</i> , 0, 11, .	2.6	0

#	ARTICLE	IF	CITATIONS
107	Uptake of COVID-19 vaccinations amongst 3,433,483 children and young people: meta-analysis of UK prospective cohorts. <i>Nature Communications</i> , 2024, 15, .	12.8	0
108	Intranasal delivery of PEA-producing <i>Lactobacillus paracasei</i> F19 alleviates SARS-CoV-2 spike protein-induced lung injury in mice. <i>Translational Medicine Communications</i> , 2024, 9, .	1.4	0
109	Update on Omicron variant and its threat to vulnerable populations. <i>Public Health in Practice</i> , 2024, 7, 100494.	1.5	0
110	Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, Japan. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 20, .	3.3	0
111	Intensive Care Unit Mortality Trends during the First Two Years of the COVID-19 Pandemic in Greece: A Multi-Center Retrospective Study. <i>Viruses</i> , 2024, 16, 488.	3.3	0
112	Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant period in Korea; using K-COV-N cohort in the National health insurance service. <i>PLoS ONE</i> , 2024, 19, e0300306.	2.5	0